CIK 0001677940 · Non-accelerated filer<br>Smaller reporting company
BeyondSpring Inc.
Sign in to watch- Ticker
- BYSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- Phone
- 646-528-4184
- Business address
- 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, SUITE 410, FLORHAM PARK, NJ, 07932
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-15 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −2,152 | $2.28 | $5K | 920,798 |
| 2025-07-14 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −801 | $2.29 | $2K | 922,950 |
| 2025-07-11 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −246 | $2.29 | $563 | 923,751 |
| 2025-07-10 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −768 | $2.28 | $2K | 923,997 |
| 2025-07-09 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −252 | $2.27 | $572 | 924,765 |
| 2025-07-08 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −9,059 | $2.29 | $21K | 925,017 |
| 2025-07-02 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −324 | $2.42 | $784 | 934,076 |
| 2025-07-01 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −600 | $2.43 | $1K | 934,400 |
| 2025-06-23 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −1,700 | $3.09 | $5K | 1,617,409 |
| 2025-06-20 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −60,000 | $3.11 | $187K | 935,000 |
| 2025-06-20 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −225,217 | $3.16 | $712K | 1,619,109 |
| 2025-06-18 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −59,253 | $3.17 | $188K | 1,844,326 |
| 2025-06-17 | Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner | Sale | −5,000 | $3.23 | $16K | 995,000 |
| 2025-04-21 | Kirkby Matthew Director | Grant or award · Stock Options (right to buy) | +25,763 | 25,763 | ||
| 2025-04-21 | Huang Lan Chief Executive Officer | Grant or award · Stock Options (right to buy) | +43,630 | 43,630 | ||
| 2025-04-21 | Delaney Brendan Director | Grant or award · Stock Options (right to buy) | +21,822 | 21,822 | ||
| 2025-04-21 | Majeti Jiangwen Director | Grant or award · Stock Options (right to buy) | +23,300 | 23,300 | ||
| 2025-04-21 | Xu Sihai Director | Grant or award · Stock Options (right to buy) | +19,852 | 19,852 | ||
| 2025-04-21 | Fabbio Patrick Director | Grant or award · Stock Options (right to buy) | +23,793 | 23,793 | ||
| 2025-04-21 | Lu Yingjuan June Chief Scientific Officer | Grant or award · Stock Options (right to buy) | +18,981 | 18,981 |
Page 4 of 4 · 80 trades